

2012

英文論文

1. 2012 Minami Y, Okumura N, Yamamoto N, Tsuji N, Kono Y, **Kudo M**: Quantification of tumor vascularity with contrast-enhanced ultrasound for early response of transcatheter arterial chemoembolization for hepatocellular carcinoma: a report of three cases. **J Med Ultrason** 28: 15-19, 2012 (IF=0.559).
2. 2012 Kitano M, **Kudo M**, Yamao K, Takagi T, Sakamoto H, Komaki T, Kamata K, Imai H, Chiba Y, Okada M, Murakami T, Takeyama Y: Characterization of small solid tumors in the pancreas: The value of contrast-enhanced harmonic endoscopic ultrasonography. **Am J Gastroenterol** 107, 303-310, 2012 (IF=10.383).
3. 2012 Sakamoto H, Kimura H, Sekijima M, Matsumoto K, Arai T, Chikugo T, Yamada Y, Kitano M, Ito A, Takeyama Y, **Kudo M**, Nishio K: Plasma concentrations of angiogenesis-related molecules in patients with pancreatic cancer. **Jpn J Clin Oncol** 42: 105-112, 2012 (IF=1.889).
4. 2012 Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A, Abecassis M, Balabaud C, Barritt GJ, Belghiti J, Bhoori S, Bossuyt P, Breitenstein S, Broelsch C, Bruix J, Burra P, Burroughs A, Busuttil R, Charlton M, Cherqui D, Colombo ML, d'Albuquerque C, D'Alessandro A, de Santibanez EJ, Dufour F, Durand F, Dutkowski P, Duvoux C, El-Serag H, Fan ST, Finn RS, Fisher R, Forner A, Freeman R, Fung J, Geier A, Germani G, Gores G, Gouw AS, Grant D, Greig P, Gurusamy K, Hanto D, Heaton N, Heim M, Hemming A, Hippen B, Hisham A, Hubscher S, Ichida T, Kahn D, Kew M, Kita Y, Kiuchi T, Klintmalm GB, Kneteman N, Kojiro M, **Kudo M**, Langer B, Lee JM, Lee SG, Lencioni R, Lerut J, Lesurtel M, Livraghi T, Llovet JM, Lo CM, Lodge P, MacCaughan G, Madoff D, Majno P, Marcellin P, Marrero J, Mazzaferro V, Mergental H, Merle P, Miksad R, Mornex F, Mullhaupt B, Olthoff K, Paradis V, Perrier A,

- Pestalozzi B, Pomfret E, Poon R, Porte R, Greig P, Prasad KR, Raptis D, Roskams T, Rossi M, Samuel D, Schlitt H, Schwartz M, Sexton Dobby AM, Shaked A, Sherman M, Siegler M, Suh KS, Todo S, Toso C, Trevisani F, Trotter JJ, Veldecasas GJ, Vauthey N, Vilgrain V, Villamil F, Vonlanthen R, Wald C, Weber A, Wiesner R, Wright L, Yao F, Zheng SS, Zucman-Rossi J: Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. **Lancet Oncol** 13: e11-22, 2012 (IF=26.509).
5. 2012 Minami Y, Kitai S, **Kudo M**: Treatment response assessment of radiofrequency ablation for hepatocellular carcinoma: Usefulness of virtual CT sonography with magnetic navigation. **Eur J Radiol** 81: e277-280, 2012 (IF=2.593).
 6. 2012 Watanabe T, Yamashita K, Fujikawa S, Sakurai T, **Kudo M**, Shiokawa M, Kodama Y, Uchida K, Okazaki K, Chiba T: Involvement activation of toll-like receptors and nucleotide-binding oligomerization domain-like receptors in enhanced IgG4 responses in autoimmune pancreatitis. **Arthritis Rheum** 64: 914-924, 2012 (IF=8.955).
 7. 2012 Takayasu K, Arii S, **Kudo M**, Ichida T, Matsui O, Izumi N, Matsuyama Y, Sakamoto M, Nakashima O, Ku Y, Kokudo N, Makuuchi M: Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. **J Hepatol** 56: 886-892, 2012 (IF=10.590).
 8. 2012 **Kudo M**, Tateishi R, Yamashita T, Ikeda M, Furuse J, Ikeda K, Kokudo N, Izumi N, Matsui O: Current status of hepatocellular carcinoma treatment in Japan: Case study and discussion-voting system. **Clin Drug Invest** 32;suppl.2:37-51, 2012 (IF=1.806).
 9. 2012 **Kudo M**: Closing remarks. **Clin Drug Invest** 32;suppl.2:52, 2012 (IF=1.806).
 10. 2012 Saito J, Kim SR, **Kuod M**, Imoto S, Ando K, Nakajima T, Fukuda K, Otono Y, Kim SK, Komaki T, Yano H, Nakashima O, Sugimoto K,

Matsuoka T: Well-differentiated hepatocellular carcinoma detected as hypovascularity by only CT during hepatic arteriography. **Intern Med** 51:885-890, 2012 (IF=0.832).

11. 2012 Lencioni R, **Kudo M**, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, Guevara LL, Papandreou C, Sanyal AJ, Takayama T, Yoon SK, Nakajima K, Cihon F, Heldner S, Marrero JA: First interim analysis of the GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) non-interventional study. **Int J Clin Pract** 66:675-683, 2012 (IF=2.226).
12. 2012 Okada M, Ishii K, Numata K, Hyodo T, Kumano S, Kitano M, **Kudo M**, Murakami T: Can the biliary enhancement of Gd-EOB-DTPA predict the degree of liver function ? **Hepatob Pancreatic Dis Int** 11:307-313, 2012 (IF=1.724).
13. 2012 **Kudo M**: Welcome to the first issue of Liver Cancer. **Liver Cancer** 1(1):1, 2012 (IF=0.000).
14. 2012 Hagiwara S, **Kudo M**, Nagai T, Inoue T, Ueshima K, Nishida N, Watanabe T, Sakurai T: Activation of JNK and high expression level of CD133 predict a poor response to Sorafenib in hepatocellular carcinoma. **Brit J Cancer** 106:1997-2003, 2012 (IF=5.569)
15. 2012 Shiina T, Maki T, Yamakawa M, Mitake T, **Kudo M**, Fujimoto K: Mechanical model analysis for quantitative evaluation of liver fibrosis based on ultrasound tissue elasticity imaging. **Jpn J Appl Phys** 51:07GF11-1-8, 2012 (IF=1.122).
16. 2012 Tsuji Y, Watanabe T, **Kudo M**, Arai H, Strober W, Chiba T: Sensing of commensal organisms by the intracellular sensor NOD1 Mediates experimental pancreatitis. **Immunity** 37:326-338, 2012 (IF=24.082).
17. 2012 Sakamoto H, Kitano M, Kamata K, Miyata T, Kadosaka K, Imai H, Takeyama Y, **Kudo M**: Transcatheter endoscopy for pancreaticobiliary duct

- diseases (with videos). **Gastrointest Endosc** 76:892-899, 2012 (IF=6.217).
18. 2012 Takahashi K, Kashida H, **Kudo M**: Hepatic nodules associated with an inferior mesenteric arteriovenous malformation. **Internal Med** 51:2753-2755, 2012 (IF=0.832).
 19. 2012 **Kudo M**: Why does every hepatocellular carcinoma clinical trial using molecular targeted agents fail? **Liver Cancer** 1(2):59-60, 2012 (IF=0.000).
 20. 2012 **Kudo M**: Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy. **Liver Cancer** 1(2):62-70, 2012 (IF=0.000).
 21. 2012 Park AM, **Kudo M**, Hagiwara S, Tabuchi M, Watanabe T, Munakata H, Sakurai T: p38MAPK suppresses chronic pancreatitis by regulating HSP27 and BAD expression. **Free Radical Bio Med** 52:2284-2291, 2012 (IF=5.784).
 22. 2012 Sakurai T, Kashida H, **Kudo M**: Case of Peutz-Jeghers syndrome with depressed-type early duodenal carcinoma. **Digest Endosc** 24:489, 2012 (IF=2.715).
 23. 2012 **Kudo M**: Viral Hepatitis and Hepatocellular carcinoma:Update in 2012. **Digest Dis** 30:539-540, 2012 (IF=1.777).
 24. 2012 Hagiwara S, Sakurai T, Nishina S, Tanaka K, Ikeda M, Ueshima K, Minami Y, Inoue T, Yada N, Kitai S, Takita M, Nagai T, Hayaishi S, Arizumi T, Park AM, Munakata H, Nishida N, **Kudo M**: Characteristic pattern of reactivation of hepatitis B virus during chemotherapy for solid cancers. **Digest Dis** 30:541-546, 2012 (IF=1.777).
 25. 2012 Nishida N, Arizumi T, Hayaishi S, Takita M, Kitai S, Yada N, Hagiwara S, Inoue T, Minami Y, Ueshima K, Sakurai T, Ikai I, **Kudo M**: Gender differences in the livers of patients with hepatocellular carcinoma and chronic hepatitis C infection. **Digest Dis** 30:547-553, 2012 (IF=1.777).

26. 2012 Ueda T, Tsuchiya K, Hashimoto S, Inoue T, Inao M, Tanaka A, Kaito M, Imazaki F, Nishiguchi S, Mochida S, Yokosuka O, Yatsushashi H, Izumi N, **Kudo M**, for RE TRY study group: Retreatment with peginterferon alfa-2a plus ribavirin in patients who failed previous peginterferon alfa-2b plus ribavirin combination therapy. **Digest Dis** 30:554-560, 2012 (IF=1.777).
27. 2012 Hagiwara S, Sakurai T, Takita M, Ueshima K, Minami Y, Inoue T, Yada N, Kitai S, Nagai T, Hayaishi S, Arizumi T, Nishida N, **Kudo M**: Risk of HCC development in cases of hepatitis C treated by long-term, low-dose PEG-IFN α 2a. **Digest Dis**, 30:561-567, 2012 (IF=1.777).
28. 2012 Kobayashi S, Kim SR, Imoto S, Ando K, Hirakawa M, Saito J, Fukuda K, Otono Y, Sakaki M, Tsuchida S, Kim SK, Hayashi Y, Nakano M, **Kudo M**: Histopathological diagnosis of early HCC through biopsy -efficacy of victoria blue and cytokeratin 7 staining-. **Digest Dis** 30:574-579, 2012 (IF=1.777).
29. 2012 Tsuchida S, Fukumoto T, Toyokawa A, Awazu M, Kusunoki N, Kido M, Takahashi M, Tanaka M, Kuramitsu K, Kim SR, **Kudo M**, Ku Y: Novel non-trocar technique for laparoscopic radiofrequency ablation. **Digest Dis** 30:588-591, 2012 (IF=1.777).
30. 2012 Minami Y, **Kudo M**: Hepatocellular carcinoma with obstructive jaundice: endoscopic and percutaneous biliary drainage. **Digest Dis** 30:592-597, 2012 (IF=1.777).
31. 2012 **Kudo M**, Ueshima K, Arizumi T: Real-life clinical practice with sorafenib in advanced hepatocellular carcinoma: a single center experience. **Digest Dis** 30:609-616, 2012 (IF=1.777).
32. 2012 Katsube T, Okada M, Kumano S, Imaoka I, Kagawa Y, Hori M, Ishii K, Tanigawa N, Imai Y, **Kudo M**, Murakami T: Estimation of liver function using T2* mapping on gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid enhanced magnetic resonance imaging. **Eur J Radiol** 81:1460-1464, 2012 (IF=2.593).

33. 2012 Nishida N, **Kudo M**, Nagasaka T, Ikai I, Goel A: Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma. **Hepatology** 56:994-1003, 2012 (IF=11.711).
34. 2012 Kitano M, Sakamoto H, **Kudo M**: Endoscopic ultrasound: contrast enhancement. **Gastrointest Endosc Clin N Am** 22:349-358, 2012.
35. 2012 **Kudo M**: Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinoma. **World J Gastroenterol** 18:6005-6017, 2012 (IF=2.787).
36. 2012 Inoue T, Kitai S, Hayaishi S, **Kudo M**: Septicemia due to vibrio cholerae serogroup non-O1/non-O139 strain in a cirrhotic patient. **Clin J Gastroenterol** 5:383-387, 2012 (IF=0.000).
37. 2012 **Kudo M**: Japan's successful model of nationwide hepatocellular carcinoma surveillance highlighting the urgent need for global surveillance. **Liver Cancer** 1(3):141-143, 2012 (IF=0.000).
38. 2012 Okusaka T, Kasugai H, Ishii H, **Kudo M**, Sata M, Tanaka K, Shioyama Y, Chayama K, Kumada H, Yoshikawa M, Seki T, Saito H, Hayashi N, Shiratori K, Okita K, Sakaida I, Honda M, Kusumoto Y, Tsutsumi T, Sakata K: A randomized phase II trial of intra-arterial chemotherapy using SM-11355 (Miriplatin) for hepatocellular carcinoma. **Invest New Drug** 30: 2015-2025, 2012 (IF=3.281).
39. 2012 Hagiwara S, **Kudo M**, Chung H, Ueshima K, Inoue T, Haji S, Watanabe T, Park AM, Munakata H, Sakurai T: Activation of c-Jun N-terminal kinase in non-cancerous liver tissue predicts a high risk of recurrence after hepatic resection for hepatocellular carcinoma. **Hepatol Res** 42: 394-400, 2012 (IF=2.208).
40. 2012 Sakurai T, **Kudo M**, Umemura A, He G, Elsharkawy AM, Seki E, Karin M: p38 α inhibits liver fibrogenesis and consequent

hepatocarcinogenesis by curtailing accumulation of reactive oxygen species. **Cancer Res** 73:215-224, 2012 (IF=8.556).

41. 2012 **Kudo M**: Targeted therapy for liver cancer: updated review in 2012. **Curr Cancer Drug Tar** 12: 1062-1072, 2012 (IF=3.707)
42. 2012 Kaneko S, Furuse J, **Kudo M**, Ikeda K, Honda M, Nakamoto Y, Onchi M, Shiota G, Yokosuka O, Sakaida I, Takehara T, Ueno Y, Hiroishi K, Nishiguchi S, Moriwaki H, Yamamoto K, Sata M, Obi S, Miyayama S, Imai Y: Guideline on the use of new anticancer drugs for the treatment of hepatocellular carcinoma 2010 update. **Hepatol Res** 42: 523-542, 2012 (IF=2.208).
43. 2012 Inoue T, **Kudo M**, Komuta M, Hayaishi S, Ueda T, Takita M, Kitai S, Hatanaka K, Yada N, Hagiwara S, Chung H, Sakurai T, Ueshima K, Sakamoto M, Maenishi O, Hyodo T, Okada M, Kumano S, Murakami T: Assessment of Gd-EOB-DTPA-enhanced MRI for HCC and Dysplastic nodule and comparison of detection sensitivity versus MDCT. **J Gastroenterol** 47: 1036-1047, 2012 (IF=4.414).